DR. HENRY RICHARD ALEXANDER JR., M.D.

Plain English
This study looks at how to treat patients with cancer that has spread throughout the liver, which can be very difficult to manage. Researchers investigated different techniques for delivering treatment directly to the liver and found that addressing liver metastases is crucial as they are often the main cause of health problems and deaths in these patients. Understanding and improving these treatment methods can lead to better outcomes for people suffering from this type of cancer. Who this helps: This helps patients with diffuse metastatic cancer in the liver and their doctors.

Plain English
This study looked at new blood tests to improve the diagnosis of different types of ovarian cancer in over 1,300 patients. Researchers found that the combined use of new markers CA125 and HE4 picked up 93% of high-grade serous ovarian cancers, which is better than using CA125 alone. This is important because early and accurate detection of ovarian cancer can lead to better treatment outcomes for patients. Who this helps: This helps patients with ovarian cancer by providing more accurate diagnostic options.

Plain English
Researchers created new guidelines for treating peritoneal mesothelioma, a rare and challenging cancer, after gathering opinions from 101 experts. They found that there was strong agreement (over 90%) on treatment strategies, particularly the importance of tailored approaches based on individual patient conditions, and the value of involving patients in clinical trials. These guidelines help ensure that patients receive better-informed and coordinated care. Who this helps: This benefits patients with peritoneal mesothelioma and their healthcare providers.

Plain English
This study focused on improving how doctors manage peritoneal mesothelioma, a rare and challenging cancer affecting the lining of the abdomen. The researchers gathered opinions from 101 experts, and found that there was a strong agreement (over 90% consensus) on guidelines for treating the disease, particularly emphasizing the need for personalized treatment plans based on each patient’s specific situation. This matters because a clear set of guidelines can help doctors make better decisions for their patients, especially when high-quality evidence is lacking. Who this helps: This helps patients with peritoneal mesothelioma and their doctors by providing clearer treatment options.

Plain English
This study looked at surgeries to remove part of the pancreas in patients with a condition called intraductal papillary mucinous neoplasm (IPMN), focusing on changes from 2014 to 2019. Out of 3,912 patients, 21% had cancer while 79% did not. Overall, the rate of surgeries remained stable, but more patients are now having robotic surgery, which increased from 9.1% to 16.5%, and the rate of a serious complication called clinically relevant postoperative pancreatic fistula dropped from 18.8% to 13.8%. Who this helps: This research benefits patients with IPMN and their doctors by highlighting improvements in surgical methods and outcomes.

Plain English
This study looked at how adjuvant chemotherapy affects patients with Stage II-IV colorectal cancer after they have had surgery to remove tumors. Researchers found that patients who received chemotherapy had significantly lower rates of cancer returning within the first year compared to those who only had surgery: 9% experienced a return of cancer within the first six months, compared to 22% in the surgery-only group. Chemo helped more in the short term, but the differences in outcomes became smaller after the first year. Who this helps: This research benefits colorectal cancer patients by highlighting the importance of chemotherapy in preventing early recurrence.

Plain English
This study looked at how race and ethnicity affect the likelihood of finding invasive tumors in patients undergoing surgery for a precancerous condition of the pancreas called intraductal papillary mucinous neoplasms. Out of 4,505 cases examined, 20.5% had invasive cancer, with Black patients at 24.2%, Asian patients at 23.7%, and Hispanic patients at 22.6%, compared to 19.9% for non-Hispanic White patients. This difference in invasive cases can't be explained by overall health or age factors, which means that non-White patients face higher risks, and recognizing this can help doctors improve early interventions and treatment strategies. Who this helps: This helps patients from diverse racial and ethnic backgrounds facing pancreatic cancer risks.

Plain English
This study looked at two types of appendiceal cancer—mucinous and non-mucinous—and how much of the tumor needs to be surgically removed to improve survival. Out of nearly 4,700 patients, 68% had their entire colon removed, and while this helped patients with non-mucinous cancer (especially those with medium to high tumor grades), it didn't improve survival for those with mucinous cancer at all. This finding suggests that patients with mucinous appendiceal adenocarcinoma might not need such extensive surgery, which could reduce unnecessary procedures and their associated risks. Who this helps: This helps patients with mucinous appendiceal cancer by potentially sparing them from more invasive surgery.

Plain English
This study examined how neighborhood wealth affects young adults (under 50) with colorectal cancer. It found that those living in poorer neighborhoods were 13% more likely to have advanced cancer when diagnosed and had a 45% higher risk of dying compared to those from wealthier areas. Additionally, non-Hispanic Black patients faced more severe outcomes, including being less likely to have surgery and having lower survival rates. Who this helps: This research benefits patients, particularly young adults with colorectal cancer and those from low-income or minority communities.

Plain English
Researchers looked at whether hospitals that perform more of a specific cancer surgery (called CRS/HIPEC, which involves removing tumors and bathing the abdomen with heated chemotherapy) get better results than hospitals that do fewer of these operations. They examined over 5,000 procedures across 149 hospitals between 2020 and 2022. They found no meaningful difference in patient outcomes—including complications, deaths, hospital stays, or readmissions—regardless of whether a hospital performed 4 cases a year or 47 cases a year. The only minor difference was that low-volume hospitals sent more patients to the ICU after surgery, but this didn't translate to worse overall results. This matters because it shows that for this particular procedure, hospitals don't need to do hundreds of these surgeries to get good results—experience at a basic level is apparently enough, at least in well-equipped academic medical centers.

Plain English
Researchers tracked cancer surgeries for the pancreas and liver during COVID-19 to see if the pandemic disrupted treatment. They found that pancreatic cancer surgeries continued at normal rates throughout the pandemic, while liver cancer surgeries dropped briefly at the start but quickly returned to normal levels—and more pancreatic cancer patients received chemotherapy before surgery during the pandemic. This matters because it shows hospitals prioritized cancer operations during COVID-19, meaning patients with these deadly cancers didn't face major treatment delays, though the increased use of pre-surgery chemotherapy suggests doctors may have changed their approach to managing these patients.

Plain English
This research paper focuses on how to effectively treat peritoneal metastasis, a form of cancer spread that affects a large number of patients, particularly those with cancers like colorectal and ovarian. The study highlights advancements in treatments, showing that combining aggressive surgery with heated chemotherapy significantly improves patient outcomes. For instance, using these combined methods has led to better symptom relief and longer survival rates compared to older treatment approaches that were often ineffective. Who this helps: This research benefits cancer patients and their doctors by providing them with improved treatment options for managing peritoneal metastasis.

Plain English
This study looked at the use of robotic surgery for a complex procedure called pancreatoduodenectomy (PD) over six years. It found that robotic surgeries increased from 2.8% to 7.5% of all PD cases, with fewer complications and shorter hospital stays compared to traditional methods—9.5 days in the hospital for robotic surgery versus 10.9 days for other types. However, medical trainees aren't getting enough practice, as there are only about 5 robotic cases per trainee each year, which is not enough to become proficient. Who this helps: This benefits patients undergoing PD by providing safer and more efficient surgical options.

Plain English
This research looked at the link between specific genetic changes (mutations) and how they affect the behavior of pancreatic cancer cells in tumors from 321 patients. The study found that 26.8% of the patients had these mutations, and while some were linked to poorer survival rates, especially in specific conditions, the mutations themselves did not affect the cancer's characteristics or patient outcomes. This means more targeted clinical trials are needed to improve treatment for pancreatic cancer. Who this helps: This helps patients with pancreatic cancer and their doctors by identifying the need for better treatment options.

Plain English
This study looked at a rare case of a 45-year-old woman who had liver masses that appeared cancerous but were actually caused by a parasitic infection transmitted through contaminated soil. After treatment with ivermectin for two weeks, her liver issues completely resolved. This is important because it shows that doctors should consider parasitic infections when diagnosing liver problems, as early treatment can lead to better outcomes and avoid unnecessary surgeries. Who this helps: This helps patients with unexplained liver issues and doctors diagnosing similar cases.

Plain English
Researchers examined how COVID-19 affected surgery rates for gut cancers across the United States from 2019 to 2022, analyzing nearly 96,000 operations on the esophagus, stomach, colon, and rectum. They found that surgery for esophageal and rectal cancers dropped significantly and stayed low throughout the pandemic, while stomach and colon cancer surgeries initially fell but bounced back to normal levels within a few months. This matters because delays in cancer surgery can allow tumors to grow and spread, potentially worsening patient outcomes and survival rates.

Plain English
This study looked at how often patients with pancreatic cancer received chemotherapy before surgery over five years and how this affected their recovery. Researchers found that the use of this treatment (called neoadjuvant therapy) rose from 24.2% in 2014 to 42.7% in 2019, and patients who received it had fewer serious complications and were more likely to have successful surgeries. Specifically, those who got neoadjuvant therapy had a 43% higher chance of optimal surgical results and lower rates of issues like infections and reoperations. Who this helps: This helps patients with pancreatic cancer by potentially improving their surgery outcomes and recovery.

Plain English
This study looked at a rare cancer called malignant peritoneal mesothelioma, which affects the lining of the abdomen. Researchers found that a combination of surgery to remove the tumor and heated chemotherapy can significantly extend survival for some patients. They also noted that combining this approach with new immunotherapy treatments targeting a protein called PD-L1 could be a promising direction for future studies. Who this helps: This benefits patients with malignant peritoneal mesothelioma who are seeking more effective treatment options.

Plain English
This study looked at patients and their families who have a specific genetic mutation called BAP1, which is linked to several types of cancer, particularly a less aggressive form of mesothelioma. Researchers found that while some patients with this mutation experience mild mesothelioma that doesn’t need immediate treatment, others may have more aggressive forms but often respond well to therapy. Monitoring these patients closely can lead to longer lives and reduce healthcare costs. Who this helps: This research benefits patients with BAP1 mutations and their families, as well as doctors treating them.

Plain English
This study looked at a protein called PD-L1 in patients with malignant peritoneal mesothelioma (MPM), a type of cancer. They found that 76% of the tumor samples tested positive for PD-L1, which may link to more aggressive forms of the disease and worse survival rates. Understanding PD-L1 levels helps researchers explore new treatments that could improve outcomes for these patients. Who this helps: This helps patients with malignant peritoneal mesothelioma by guiding future treatment options.

Plain English
This study looked at two uncommon diseases in one patient: desmoid-type fibromatosis (a benign tumor) and malignant peritoneal mesothelioma (a serious cancer). The patient, a 30-year-old woman, had a large mass in her abdomen that was thought to be a recurrence of her cancer. After surgery to remove the mass, doctors found it was actually desmoid-type fibromatosis, not cancer, and since the tumor margins were clear, she won’t need additional treatment right now, although she will be monitored closely for any future issues. Who this helps: This information is beneficial for doctors treating patients with unusual tumors and those living with malignant peritoneal mesothelioma.

Plain English
This study examined how surgery impacts survival for patients with advanced gastric cancer that has spread to other parts of the body. Researchers analyzed data from nearly 19,000 patients and found that those who had surgery on the primary tumor or distant sites lived longer, with a median survival of about 15.8 to 15.9 months, compared to just 8.6 months for patients who did not have surgery. This is important because it shows that surgery can significantly improve survival, encouraging more exploration of surgical options for these patients. Who this helps: This helps patients with metastatic gastric cancer and their healthcare providers.

Plain English
This study looked at how metabolic syndrome (which includes obesity, diabetes, and high blood pressure) affects patients undergoing a specific type of surgery called pancreatoduodenectomy (PD). It found that 7.3% of the 19,054 patients studied had metabolic syndrome, and those patients faced higher risks: for example, 30-day mortality was 3% for those with metabolic syndrome compared to 1.8% for those without, and serious complications occurred in 26% of patients with metabolic syndrome versus 23% in others. This is important because it highlights the need for special care strategies to help reduce risks for these patients during and after surgery. Who this helps: This helps patients with metabolic syndrome who are undergoing surgery, as well as the doctors treating them.

Plain English
Researchers studied how changing cancer treatment meetings from in-person to virtual formats affected attendance and the number of cases discussed. They found that attendance increased by 46%, with 4,030 virtual attendees compared to 2,753 in-person, and the number of patient cases presented rose by 20%, from 2,127 to 2,656. This is important because it shows that virtual meetings make it easier for healthcare providers to collaborate on complex cancer cases, ensuring patients receive better care. Who this helps: This helps patients by improving access to expert cancer care through increased doctor participation.

Plain English
This study looked at ways to improve treatment for patients with cancer that has spread to the liver. Researchers found that both open and minimally invasive (percutaneous) techniques for delivering treatment directly to the liver can help manage these patients' conditions effectively. This is important because issues with the liver from cancer are often the biggest threats to the health and survival of these patients. Who this helps: Patients with diffuse metastatic cancer to the liver.

Plain English
Researchers looked at the effects of neoadjuvant therapy (NAT) on patients with early-stage pancreatic cancer who underwent surgery. They found that using NAT reduced the rates of positive margins—where cancer cells are found at the edges of the removed tissue—from 21.8% to 15.5%. When radiation therapy was also used, those rates dropped even further to 13.4%. This is important because having fewer positive margins is linked to better survival rates, with patients having positive margins living an average of 14.9 months compared to 23.9 months for those without. Who this helps: This helps patients with early-stage pancreatic cancer and their doctors in making informed treatment decisions.

Plain English
This study looked at how the COVID-19 pandemic affected cancer surgery practices at a major cancer center in the Northeastern U.S. During the pandemic months (March-April 2020), new patient visits dropped significantly, with 25.8% fewer surgeries for soft tissue tumors and a 43.6% decrease for gynecologic cancers. This matters because it shows that many cancer patients couldn't receive timely surgical care, highlighting the need for telehealth options to improve patient access during crises. Who this helps: Patients and healthcare providers in cancer treatment.

Plain English
This study looked at how a protein called Desmoglein-2 (Dsg2) affects how cells spread out and attach to their surroundings, even when they aren't sticking to other cells. Researchers found that cells missing Dsg2 spread out more on fibronectin and collagen, growing to three times the area of normal cells. This is important because it reveals a new way that Dsg2 helps cells adapt and move, which could have implications for understanding various cell functions and diseases. Who this helps: This research benefits scientists and healthcare professionals studying cell behavior in diseases such as cancer.

Plain English
This study looked at how two different chemotherapy drugs, capecitabine (CAPE) and gemcitabine (GEM), performed in combination with radiation therapy before surgery in patients with borderline resectable and resectable pancreatic cancer. It found that patients taking CAPE had a much better chance of having their tumors surgically removed (almost 10 times more likely) and lived longer without their cancer worsening (15.4 months compared to 4.0 months for GEM). Thus, using CAPE may improve treatment outcomes for these patients. Who this helps: This research benefits pancreatic cancer patients who are considering surgery.

Plain English
This study looked at how certain metabolic processes affect the severity of pancreatic cancer. Researchers found that a compound called kynurenine, linked to an enzyme called NOS2, was present in higher levels in patients with more aggressive tumors, and those with more kynurenine had a 10% lower chance of survival. Understanding this relationship could lead to new treatment strategies for pancreatic cancer. Who this helps: This helps patients with pancreatic cancer.

Plain English
This study looked at how two drugs, verteporfin and CA3, can fight mesothelioma, a tough cancer that can resist treatments. The researchers found that both drugs reduced the ability of cancer stem cells to form tumors and spread, enhancing cell death. Specifically, treatment with these drugs decreased tumor growth and invasion significantly. This is important because it offers a potential new way to target the most aggressive cancer cells that often survive treatments. Who this helps: This benefits patients with mesothelioma by providing new treatment options that may improve outcomes.

Plain English
This study examines malignant peritoneal mesothelioma (MPM), a rare and aggressive cancer affecting the lining of the abdomen. It highlights that patients with MPM who can undergo surgery and receive a specific treatment called CRS-HIPEC might survive over 5 years, while those with inoperable cases often do not respond well to standard chemotherapy. This research is important because it improves understanding of MPM and emphasizes the need for specialized care, potentially leading to new treatments and better outcomes for patients. Who this helps: Patients with malignant peritoneal mesothelioma and their doctors.

Plain English
This study focused on how different racial and ethnic groups use medical services for liver cancer linked to hepatitis C. Researchers found that from 2005 to 2015, Black and Hispanic patients received fewer treatments—like liver transplants and surgeries—compared to white patients, leading to worse outcomes; specifically, Black patients had higher death rates during hospitalization. This matters because it highlights important health disparities that need to be addressed to ensure everyone receives fair medical care. Who this helps: This helps patients, especially those from Black and Hispanic communities dealing with liver cancer.

Plain English
This research looked at different subcategories of T1 stage pancreatic cancer to see how they affect survival rates in patients who had surgery. They analyzed data from over 41,000 patients and found that the 5-year survival rates for T1a (68.8%), T1b (57%), and T1c (46.6%) patients showed differences, indicating that smaller tumors generally lead to better outcomes. However, when looking at a more in-depth analysis, the distinction between the categories was not significant across all cases. Who this helps: This benefits patients with pancreatic cancer and their doctors by providing clearer survival expectations based on tumor size.

Plain English
This study looked at mesothelioma, a type of cancer mostly affecting older people exposed to asbestos, and found that while rates of new cases are falling in some wealthy countries, the overall death rates haven't dropped due to an aging population. It highlighted that up to 50% of diagnoses in developing countries might be wrong, which leads to ineffective treatments and complicates understanding of the disease. The research also identified specific gene mutations (BAP1) related to mesothelioma and is exploring new treatments that target these genetic factors, showing promise especially for a specific form known as peritoneal mesothelioma. Who this helps: This research benefits patients with mesothelioma and healthcare providers involved in their diagnosis and treatment.

Plain English
This study looked at patients with HIV who had major surgeries to remove cancers that are not related to AIDS, comparing their recovery to that of the general population. Researchers found that HIV patients had a higher risk of complications after surgery, particularly after lung surgery, where their risk was nearly three times greater. It also took HIV patients longer to recover after surgery, especially after colectomy, averaging about 2.6 more days in the hospital. Who this helps: This information benefits doctors and healthcare providers treating HIV patients with cancer.

Plain English
This study explored how a new form of the compound thymoquinone (TQ), delivered in tiny fat-like particles called Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC), affects wound healing in normal and diabetic cells. The researchers found that TQ-NLC improved the survival and growth of cells, with up to 95% healthy cells in some cases, and helped these cells move and multiply more effectively compared to regular TQ. This is important because it suggests that TQ-NLC could be a more effective treatment for improving wound healing, particularly in patients with diabetes who often struggle with healing their wounds. Who this helps: Patients, especially those with diabetes.

Plain English
The study reviewed the current understanding and treatment approaches for peritoneal mesothelioma, a rare and deadly cancer that typically affects people aged 55 to 60. It found that without treatment, patients usually survive for less than a year, but some treatments, like a combination of certain chemotherapy drugs or surgical options paired with special chemotherapy techniques, can lead to longer survival for selected patients. Understanding the biology of this cancer has also opened up potential new treatments that target specific pathways in the cancer cells. Who this helps: This research benefits patients diagnosed with peritoneal mesothelioma and their healthcare providers.

Plain English
This study looked at patients with Zollinger-Ellison Syndrome (ZES) who had surgery but later experienced a return of their disease. Of the 223 patients who initially had surgery, 52 (23%) needed another operation due to disease recurrence. After this second surgery, 35% of them were free of the disease right away, and 25% remained disease-free after about 8 years. This is important because it shows that many patients can have longer survival and even a potential cure with a second surgery if their disease comes back. Who this helps: This helps patients with Zollinger-Ellison Syndrome and their doctors by highlighting the benefits of reoperation for recurrent disease.

Plain English
This study focused on malignant peritoneal mesothelioma (MPM), a rare and fatal cancer that usually affects the abdomen. It found that nearly all patients with MPM will die from the disease due to its tendency to spread aggressively within the abdominal cavity, often leading to diagnosis only at an advanced stage. Understanding MPM is crucial since it does not respond well to chemotherapy and most patients face a poor prognosis. Who this helps: This information benefits patients, doctors, and researchers working on treatment options for rare cancers.

Plain English
This study focused on a protein called transglutaminase 2 (TG2), which was found to be crucial for the survival of mesothelioma cancer stem cells. Researchers discovered that when they reduced the levels of TG2 or blocked its activity, the cancer cells formed tumors more slowly, with the time for tumors to first appear doubling in cells without TG2. This is significant because targeting TG2 could lead to better treatments for mesothelioma, a cancer that is often resistant to current therapies and has a poor outlook. Who this helps: This benefits patients with mesothelioma, offering hope for more effective treatment options.